Linked Life Data

17881328

Source:http://linkedlifedata.com/resource/pubmed/id/17881328

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2007-9-20
pubmed:abstractText
Insulin detemir (Levemir [Novo Nordisk A/S, Bagsvaerd, Denmark]) is a soluble, long-acting basal insulin analog. It differs from human insulin in that the amino acid threonine in position B30 has been removed and a 14-carbon fatty acid (myristic acid) has been acylated to lysine at B29. This modification increases self-association and enables albumin binding of insulin detemir. In this manuscript, the unique molecular properties and the resulting pharmacodynamics of insulin detemir are reviewed. The protracted duration of action, smooth activity profile, and low intrapatient variability of insulin detemir are presented as properties that may potentially help patients maximize glycemic control and minimize the long-term complications of diabetes.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0889-8529
pubmed:author
pubmed:issnType
Print
pubmed:volume
36 Suppl 1
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
14-20
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Pharmacology of insulin detemir.
pubmed:affiliation
Diabetes Research, Novo Nordisk A/S, Bagsvaerd, Copenhagen, Denmark. pkur@novonordisk.com
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't